Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 23, 2022 3:45pm

144 Views

Post# 35190309

RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

December 23, 2022 - Biospace reports - 2022 M&A activity in the life sciences sector failed to meet expectations, but Amgen’s recent $26.4 million buy-out of Horizon Therapeutics may be a sign of bigger things to come.

PwC certainly thinks so, predicting a total deal value in the $225 billion to $275 billion range across all subsectors. The firm credits this anticipated upswing to a somewhat stabilized economic outlook, a need to close medium-term pipeline gaps, the resolution of the U.S. midterm elections and a better understanding of the impacts of the Inflation Reduction Act.

PwC predicts: